Director, In Vivo Pharmacology and Disease Biology

THE COMPANY

Prolynx is a preclinical biotechnology company with a vision to become the industry leader in ultra-long-acting medicines that improve outcomes for patients with obesity, cardiometabolic, and other diseases. The company is developing a next-generation portfolio of incretin and non-incretin therapeutics designed for once-monthly and once-quarterly dosing. Its proprietary, first-in-category platform uses a hydrogel-based microsphere technology with independently tunable release-linker chemistry to enable highly predictable pharmacokinetics and sustained drug exposure. Prolynx is backed by leading investors including 5AM Ventures, OrbiMed, and Monograph Capital and is based in Emeryville, CA.

Join a multidisciplinary team of talented scientists developing innovative and differentiated medicines - where we pursue purposeful science and let data and patient needs drive decisions. Prolynx provides an environment where you work, learn, and grow alongside experienced drug developers, inventive scientists, and business professionals. Bring your passion, creativity, and energy to our mission. At Prolynx, contributions are valued regardless of title, people are trusted to own their area of expertise, and teammates readily step in to help one another. We share what we know and succeed together. If that sounds like the place for you, we’d like to meet you.

The Role

We are seeking an experienced scientific leader to build and direct our In Vivo Pharmacology and Disease Biology function. In this newly created role, you will set the strategic direction for in vivo pharmacology across the portfolio, lead / manage a network of CRO partnerships with an opportunity, over time, to build an internal team. As a member of the Preclinical Leadership Team, you will serve as a senior scientific voice shaping program strategy, resourcing and go/no-go decisions alongside the Chief Scientific Officer and other functional leaders.

You will design and validate disease-relevant animal models in mice, rats and non-human primates (NHPs) to test, rank, and characterize innovative sustained release therapies. You will demonstrate the efficacy across full monthly or quarterly dosing intervals, define the exposure-response relationships to enable human dose projections and ascertain the impact on the molecular disease pathobiology of the indications being studied. The candidate will assess the impact of our novel and differentiated therapies on disease comorbidities and biomarkers; and, has demonstrated experience in rigorous data analysis, interpreting and writing pharmacology reports and authoring the preclinical / pharmacology sections of IND submissions and other regulatory documents as programs move from lead selection through candidate nomination and into the clinic.